Program
Brentuximab Vedotin
Also written as “brentuximab vedotin”, “Brentuximab vedotin” and “SGN-35”.
Its studies are mostly in Hodgkin Disease · Lymphoma, Large-Cell, Anaplastic · Lymphoma, Large B-Cell, Diffuse · Lymphoma, T-Cell, Peripheral · Melanoma, led by 3 companies.
Drug pageBrentuximab Vedotin: every studyAll 154 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 241 open or running | phase 3since Apr 6, 2010 | Feb 1, 2007 | none ahead |
| Takeda | 113 open or running | phase 4since Jul 1, 2013 | Dec 12, 2011 | Mar 31, 2028phase 4 · NCT06831370 |
| Bristol-Myers Squibbits history only | 20 open or running | phase 3since May 1, 2017 | Oct 13, 2015 | none ahead |
Also a collaborator on its studies: Merck, Takeda Development Center Americas and Ono Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Takeda only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2011First study: phase 2 study in RecurrenceFirst studyNCT01492088 · 36 enrolled · United States, France, Germany and more
- Mar 27, 2012Phase 3 study in Lymphoma, Primary Cutaneous Anaplastic Large CellNCT01578499 · 131 enrolled · United States, Australia, Austria and more
- Oct 19, 2012Phase 3 study in Hodgkin DiseaseNCT01712490 · 1,334 enrolled · United States, Australia, Belgium and more
- Jul 1, 2013Phase 4 study in LymphomaNCT01909934 · 50 enrolled · Belgium, Croatia, Czechia and more
- Sep 23, 2013Phase 1 study in Hodgkin DiseaseNCT01950364 · 20 enrolled · Belgium, Lithuania, Spain
- Nov 15, 2013Phase 4 study in Hodgkin DiseaseNCT01990534 · 60 enrolled · Czechia, Germany, Malaysia and more
- Oct 18, 2016Phase 2 study in Hodgkin DiseaseNCT02939014 · 39 enrolled · China
- Nov 11, 2016Phase 2 study in Hodgkin DiseaseNCT02979522 · 59 enrolled · United States, Brazil, Italy and more
- Jun 30, 2022Phase 4 study in Lymphoma, T-CellNCT05442554 · 10 enrolled · China
- Jan 4, 2023Phase 2 study in LymphomaNCT05673785 · 52 enrolled · China
- Feb 14, 2025Phase 4 study in Hodgkin DiseaseNCT06831370 · 124 planned · India
Ahead
- Mar 31, 2028Primary completion: phase 4 study in Hodgkin DiseaseNCT06831370
TargetBeta
“An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 8 binding agent”ChEMBL 37, by rule
Studies
All 11 Takeda leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06831370Hodgkin Disease · India | 4 | Recruiting | Mar 31, 2028 | 124 |
| NCT05673785Lymphoma · China | 2 | Active, not recruiting | Apr 27, 2025 | 52 |
| NCT05442554Lymphoma, T-Cell · China | 4 | Completed | Aug 9, 2024 | 10 |
| NCT02979522Hodgkin Disease · United States, Brazil, Italy and more | 2 | Active, not recruiting | May 5, 2020 | 59 |
| NCT02939014Hodgkin Disease · China | 2 | Completed | Aug 2, 2018 | 39 |
| NCT01990534Hodgkin Disease · Czechia, Germany, Malaysia and more | 4 | Completed | Mar 24, 2016 | 60 |
| NCT01950364Hodgkin Disease · Belgium, Lithuania, Spain | 1 | Completed | Oct 2014 | 20 |
| NCT01909934Lymphoma · Belgium, Croatia, Czechia and more | 4 | Completed | May 4, 2021 | 50 |
| NCT01712490Hodgkin Disease · United States, Australia, Belgium and more | 3 | Completed | Apr 20, 2017 | 1,334 |
| NCT01578499Lymphoma, Primary Cutaneous Anaplastic Large Cell · United States, Australia, Austria and more | 3 | Completed | May 31, 2016 | 131 |
| NCT01492088Recurrence · United States, France, Germany and more | 2 | Completed | Oct 12, 2016 | 36 |
How it is read
Names in the registry
- “brentuximab vedotin”, 27 entries
- “Brentuximab vedotin”, 7 entries
- “Brentuximab Vedotin”, 7 entries
- “SGN-35”, 2 entries
- “Brentuximab vedotin and rifampicin”, 1 entry
Conditions, from the studies’ own filings
- Hodgkin Disease, 18 studies
- Lymphoma, Large-Cell, Anaplastic, 5 studies
- Lymphoma, Large B-Cell, Diffuse, 4 studies
- Lymphoma, T-Cell, Peripheral, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.